1
|
Shen Y, He J, Liu M, Hu J, Wan Y, Zhang T, Ding J, Dong J, Fu X. Diagnostic value of contrast-enhanced ultrasound and shear-wave elastography for small breast nodules. PeerJ 2024; 12:e17677. [PMID: 38974410 PMCID: PMC11227273 DOI: 10.7717/peerj.17677] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Accepted: 06/12/2024] [Indexed: 07/09/2024] Open
Abstract
Background The study aims to evaluate the diagnostic efficacy of contrast-enhanced ultrasound (CEUS) and shear-wave elastography (SWE) in detecting small malignant breast nodules in an effort to inform further refinements of the Breast Imaging Reporting and Data System (BI-RADS) classification system. Methods This study retrospectively analyzed patients with breast nodules who underwent conventional ultrasound, CEUS, and SWE at Gongli Hospital from November 2015 to December 2019. The inclusion criteria were nodules ≤ 2 cm in diameter with pathological outcomes determined by biopsy, no prior treatments, and solid or predominantly solid nodules. The exclusion criteria included pregnancy or lactation and low-quality images. Imaging features were detailed and classified per BI-RADS. Diagnostic accuracy was assessed using receiver operating characteristic curves. Results The study included 302 patients with 305 breast nodules, 113 of which were malignant. The diagnostic accuracy was significantly improved by combining the BI-RADS classification with CEUS and SWE. The combined approach yielded a sensitivity of 88.5%, specificity of 87.0%, positive predictive value of 80.0%, negative predictive value of 92.8%, and accuracy of 87.5% with an area under the curve of 0.877. Notably, 55.8% of BI-RADS 4A nodules were downgraded to BI-RADS 3 and confirmed as benign after pathological examination, suggesting the potential to avoid unnecessary biopsies. Conclusion The integrated use of the BI-RADS classification, CEUS, and SWE enhances the accuracy of differentiating benign and malignant small breast nodule, potentially reducing the need for unnecessary biopsies.
Collapse
Affiliation(s)
- Yan Shen
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Jie He
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Miao Liu
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Jiaojiao Hu
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Yonglin Wan
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Tingting Zhang
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| | - Jun Ding
- Department of Pathology, Gongli Hospital, Shanghai, China
| | - Jiangnan Dong
- Department of Surgery, Gongli Hospital, Shanghai, China
| | - Xiaohong Fu
- Department of Medical Ultrasound, Gongli Hospital, Shanghai, China
| |
Collapse
|
2
|
Aristizabal C, Suther S, Yao Y, Behar-Horenstein LS, Webb F, Stern MC, Baezconde-Garbanati L. Training Community African American and Hispanic/Latino/a Advocates on Prostate Cancer (PCa): a Multicultural and Bicoastal Approach. JOURNAL OF CANCER EDUCATION : THE OFFICIAL JOURNAL OF THE AMERICAN ASSOCIATION FOR CANCER EDUCATION 2023; 38:1719-1727. [PMID: 37452225 PMCID: PMC10509110 DOI: 10.1007/s13187-023-02326-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Accepted: 06/05/2023] [Indexed: 07/18/2023]
Abstract
African American communities are disproportionately impacted by prostate cancer (PCa) compared to other racial/ethnic groups. Whereas the incidence of PCa in Hispanic/Latino men is lower than the incidence in non-Hispanic/Latino White men, Hispanic/Latino men are more likely to be diagnosed with PCa in late stages, and less likely to be knowledgeable about PCa, resulting in significant disparities. We developed, culturally adapted, translated, implemented, and evaluated a PCa Cancer Advocacy Training in African American and Hispanic/Latino/a communities. Culturally and language specific content for African American and Hispanic/Latino/a patients on PCa causes, risk factors, epidemiology, detection, diagnosis, and treatment were delivered through a workshop and simultaneously broadcasted in Spanish in Los Angeles County (n = 29) and in English in Tallahassee, FL (n = 9). Pre- and posttest surveys assessed impact. Pre vs post differences were statistically significant in knowledge (5.0 ± 1.6 vs 6.3 ± 1.1) and advocacy intentions (3.9 ± 0.9 vs 4.3 ± 0.8), on correctly identifying warning signs for PCa (50% vs 87%), intent to inform and educate about PCa within the next 3 months (69% vs 95%), to ensure that high-quality research is sensitive to the priorities of patients (63% vs 84%), to help increase patient recruitment, compliance, and retention for clinical trials within the next month (62% vs 84%), intent to engage in PCa patient education within the next 3 months (67% vs 92%), and in engaging in PCa community outreach within the next 3 months (67% vs 94%). There were no significant differences due to race/ethnicity. The Cancer Advocacy Training led to increased knowledge, awareness, and intention to engage in advocacy regarding PCa in the next 3 months. Results suggest that delivering culturally and language specific educational information increases engagement of Hispanic/Latino/a and African American patient/community advocates.
Collapse
Affiliation(s)
- Carolina Aristizabal
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA.
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA.
| | - Sandra Suther
- College of Pharmacy & Pharmaceutical Sciences, Institute of Public Health, Florida Mechanical and Agricultural University (FAMU), Tallahassee, USA
| | - Yingwei Yao
- College of Medicine, Department of Surgery, University of Florida (UF), Gainesville, USA
| | | | - Fern Webb
- College of Medicine, Department of Surgery, University of Florida (UF), Gainesville, USA
| | - Mariana C Stern
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
| | - Lourdes Baezconde-Garbanati
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
- Norris Comprehensive Cancer Center, University of Southern California, Los Angeles, CA, USA
| |
Collapse
|
3
|
Kwolek DG, Gerstberger S, Tait S, Qiu JM. Ovarian, Uterine, and Vulvovaginal Cancers: Screening, Treatment Overview, and Prognosis. Med Clin North Am 2023; 107:329-355. [PMID: 36759101 DOI: 10.1016/j.mcna.2022.10.016] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023]
Abstract
Ovarian, uterine, and vulvovaginal cancers affect approximately 96,000 women per year in the United States, resulting in approximately 29,000 deaths annually. Routine screening protocols do not detect these malignancies; thus, the recognition of risk factors and evaluation of worrisome symptoms are essential for early detection and improved prognoses. Treatment is managed by gynecologic oncologists, and often involves a combination of surgery, chemotherapy, and possible radiation treatments. Survivor care is managed by the primary-care clinician: expert attention to the mental, physical, and sexual health of each patient will ensure the best outcomes and quality of life.
Collapse
Affiliation(s)
- Deborah Gomez Kwolek
- Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA.
| | - Stefanie Gerstberger
- Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA
| | - Sarah Tait
- Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA
| | - Jeanna M Qiu
- Department of Medicine, Massachusetts General Hospital, 55 Fruit Street, Boston, MA 02114, USA; Harvard Medical School, 25 Shattuck Street, Boston, MA 02115, USA
| |
Collapse
|
4
|
Hereditary Women's Cancer: Management and Risk-Reducing Surgery. MEDICINA (KAUNAS, LITHUANIA) 2023; 59:medicina59020300. [PMID: 36837501 PMCID: PMC9967188 DOI: 10.3390/medicina59020300] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Revised: 01/24/2023] [Accepted: 01/31/2023] [Indexed: 02/10/2023]
Abstract
Hereditary women's syndromes due to inherited mutations result in an elevated risk of developing gynecological cancers over the lifetime of affected carriers. The BRCA 1 and 2 mutations, Lynch syndrome (LS), and mutations in rare hereditary syndromes increase this risk and require more effective management of these patients based on surveillance and prophylactic surgery. Patients need counseling regarding risk-reducing surgery (RRS) and the time required to perform it, considering the adverse effects of premenopausal surgery and the hormonal effect on quality of life, bone density, sexual activity, and cardiological and vascular diseases. Risk-reducing salpingo-oophorectomy (RRSO) is the gold standard for BRCA-mutated patients. An open question is that of endometrial cancer (EC) risk in patients with BRCA1/2 mutation to justify prophylactic hysterectomy during RRSO surgical procedures. RRS provides a 90-95% risk reduction for ovarian and breast cancer in women who are mutation carriers, but the role of prophylactic hysterectomy is underinvestigated in this setting of patients. In this review, we evaluate the management of the most common hereditary syndromes and the benefits of risk-reducing surgery, particularly exploring the role of prophylactic hysterectomy.
Collapse
|
5
|
Hipp LE, Hulswit BB, Milliron KJ. Clinical Tools and Counseling Considerations for Breast Cancer Risk Assessment and Evaluation for Hereditary Cancer Risk. Best Pract Res Clin Obstet Gynaecol 2022; 82:12-29. [DOI: 10.1016/j.bpobgyn.2022.02.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2022] [Revised: 02/01/2022] [Accepted: 02/02/2022] [Indexed: 11/28/2022]
|
6
|
Al-Zahrani MH, Yahya FM, Assidi M, Dallol A, Buhmeida A. Klotho promoter methylation status and its prognostic value in ovarian cancer. Mol Clin Oncol 2021; 15:181. [PMID: 34277000 PMCID: PMC8278383 DOI: 10.3892/mco.2021.2343] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/14/2021] [Accepted: 05/21/2021] [Indexed: 01/22/2023] Open
Abstract
Among all gynecological cancers, ovarian cancer (OC) is one of the deadliest types of cancer worldwide. Epigenetic silencing of some genes has been reported to be associated with OC. In this context, Klotho (KL) gene methylation is a promising biomarker for OC. The present study aimed to investigate the methylation profiles of KL and assess its prognostic value. A total of 63 formalin-fixed paraffin-embedded tissue samples from patients with primary OC were collected and analyzed in the present study. The methylation profiles of KL were assessed by performing DNA bisulfate treatment followed by DNA promoter methylation analysis using the MethyLight assay. The results revealed KL promoter hypermethylation in 62% of the OC cohort. Additionally, significant associations were observed between KL methylation profiles and tumor subtype (P<0.0001) and tumor site (P=0.039). Furthermore, Kaplan-Meier analysis revealed that a worse disease-specific survival was significantly associated with hypermethylated KL (P=0.03, log-rank; hazard ration, 0.58; 95% confidence interval (CI), 0.26-0.90). Cox regression multivariate analysis indicated that KL promoter methylation was an independent OC prognostic indicator (P=0.029). The current study suggested that KL may be a novel biomarker to predict prognosis in patients with OC, since patients with higher KL promoter methylation were more likely to have a poor prognosis and would therefore require frequent follow-up and integrative personalized therapeutic approaches.
Collapse
Affiliation(s)
- Maryam H. Al-Zahrani
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Fatimah M. Yahya
- Biochemistry Department, Faculty of Science, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Mourad Assidi
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
- Medical Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Ashraf Dallol
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
- Medical Technology Department, Faculty of Applied Medical Sciences, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| | - Abdelbaset Buhmeida
- Center of Excellence in Genomic Medicine Research, King Abdulaziz University, Jeddah 21589, Saudi Arabia
| |
Collapse
|
7
|
Distribution of Estimated Lifetime Breast Cancer Risk Among Women Undergoing Screening Mammography. AJR Am J Roentgenol 2021; 217:48-55. [PMID: 33978450 DOI: 10.2214/ajr.20.23333] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
Abstract
OBJECTIVE. Supplemental screening breast MRI is recommended for women with an estimated lifetime risk of breast cancer of greater than 20-25%. The performance of risk prediction models varies for each individual and across groups of women. The present study investigates the concordance of three breast cancer risk prediction models among women presenting for screening mammography. SUBJECTS AND METHODS. In this prospective study, we calculated the estimated lifetime risk of breast cancer using the modified Gail, Tyrer-Cuzick version 7, and BRCAPRO models for each woman who presented for screening mammography. Per American Cancer Society guidelines, for each woman the risk was categorized as less than 20% or 20% or greater as well as less than 25% or 25% or greater with use of each model. Venn diagrams were constructed to evaluate concordance across models. The McNemar test was used to test differences in risk group allocations between models, with p ≤ .05 considered to denote statistical significance. RESULTS. Of 3503 screening mammography patients who underwent risk stratification, 3219 (91.9%) were eligible for risk estimation using all three models. Using at least one model, 440 (13.7%) women had a lifetime risk of 20% or greater, including 390 women (12.1%) according to the Tyrer-Cuzick version 7 model, 18 (0.6%) according to the BRCAPRO model, and 141 (4.4%) according to the modified Gail model. Six women (0.2%) had a risk of 20% or greater according to all three models. Women were significantly more likely to be classified as having a high lifetime breast cancer risk by the Tyrer-Cuzick version 7 model compared with the modified Gail model, with thresholds of 20% or greater (odds ratio, 6.4; 95% CI, 4.7-8.7) or 25% or greater (odds ratio, 7.4; 95% CI, 4.7-11.9) used for both models. CONCLUSION. To identify women with a high lifetime breast cancer risk, practices should use estimates of lifetime breast cancer risk derived from multiple risk prediction models.
Collapse
|
8
|
Fung SM, Wu RR, Myers RA, Goh J, Ginsburg GS, Matchar D, Orlando LA, Ngeow J. Clinical implementation of an oncology-specific family health history risk assessment tool. Hered Cancer Clin Pract 2021; 19:20. [PMID: 33743786 PMCID: PMC7981979 DOI: 10.1186/s13053-021-00177-y] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2020] [Accepted: 03/10/2021] [Indexed: 11/22/2022] Open
Abstract
BACKGROUND The presence of hereditary cancer syndromes in cancer patients can have an impact on current clinical care and post-treatment prevention and surveillance measures. Several barriers inhibit identification of hereditary cancer syndromes in routine practice. This paper describes the impact of using a patient-facing family health history risk assessment platform on the identification and referral of breast cancer patients to genetic counselling services. METHODS This was a hybrid implementation-effectiveness study completed in breast cancer clinics. English-literate patients not previously referred for genetic counselling and/or gone through genetic testing were offered enrollment. Consented participants were provided educational materials on family health history collection, entered their family health history into the platform and completed a satisfaction survey. Upon completion, participants and their clinicians were given personalized risk reports. Chart abstraction was done to identify actions taken by patients, providers and genetic counsellors. RESULTS Of 195 patients approached, 102 consented and completed the study (mean age 55.7, 100 % women). Sixty-six (65 %) met guideline criteria for genetic counseling of which 24 (36 %) were referred for genetic counseling. Of those referred, 13 (54 %) participants attended and eight (33 %) completed genetic testing. On multivariate logistic regression, referral was not associated with age, cancer stage, or race but was associated with clinical provider (p = 0.041). Most providers (71 %) had higher referral rates during the study compared to prior. The majority of participants found the experience useful (84 %), were more aware of their health risks (83 %), and were likely to recommend using a patient-facing platform to others (69 %). CONCLUSIONS 65 % of patients attending breast cancer clinics in this study are at-risk for hereditary conditions based on current guidelines. Using a patient-facing risk assessment platform enhances the ability to identify these patients systematically and with widespread acceptability and recognized value by patients. As only a third of at-risk participants received referrals for genetic counseling, further understanding barriers to referral is needed to optimize hereditary risk assessment in oncology practices. TRIAL REGISTRATION NIH Clinical Trials registry, NCT04639934 . Registered Nov 23, 2020 -- Retrospectively registered.
Collapse
Affiliation(s)
- Si Ming Fung
- Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
| | - R Ryanne Wu
- Centre for Applied Genomics and Precision Medicine, Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA.
- Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA.
- Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore.
| | - Rachel A Myers
- Centre for Applied Genomics and Precision Medicine, Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
| | - Jasper Goh
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| | - Geoffrey S Ginsburg
- Centre for Applied Genomics and Precision Medicine, Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
- Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
| | - David Matchar
- Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
- Program in Health Services and Systems Research, Duke-NUS Medical School, Singapore, Singapore
| | - Lori A Orlando
- Centre for Applied Genomics and Precision Medicine, Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
- Department of Medicine, Duke University School of Medicine, 304 Research Dr. Box 90141, Office 264, North Carolina, 27708, Durham, USA
| | - Joanne Ngeow
- Cancer Genetics Service, Division of Medical Oncology, National Cancer Centre Singapore, Singapore, Singapore
- Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore, Singapore
| |
Collapse
|
9
|
Wang Y, Nie H, He X, Liao Z, Zhou Y, Zhou J, Ou C. The emerging role of super enhancer-derived noncoding RNAs in human cancer. Theranostics 2020; 10:11049-11062. [PMID: 33042269 PMCID: PMC7532672 DOI: 10.7150/thno.49168] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2020] [Accepted: 08/23/2020] [Indexed: 02/06/2023] Open
Abstract
Super enhancers (SEs) are large clusters of adjacent enhancers that drive the expression of genes which regulate cellular identity; SE regions can be enriched with a high density of transcription factors, co-factors, and enhancer-associated epigenetic modifications. Through enhanced activation of their target genes, SEs play an important role in various diseases and conditions, including cancer. Recent studies have shown that SEs not only activate the transcriptional expression of coding genes to directly regulate biological functions, but also drive the transcriptional expression of non-coding RNAs (ncRNAs) to indirectly regulate biological functions. SE-derived ncRNAs play critical roles in tumorigenesis, including malignant proliferation, metastasis, drug resistance, and inflammatory response. Moreover, the abnormal expression of SE-derived ncRNAs is closely related to the clinical and pathological characterization of tumors. In this review, we summarize the functions and roles of SE-derived ncRNAs in tumorigenesis and discuss their prospective applications in tumor therapy. A deeper understanding of the potential mechanism underlying the action of SE-derived ncRNAs in tumorigenesis may provide new strategies for the early diagnosis of tumors and targeted therapy.
Collapse
|
10
|
Hussein N, Malik TFA, Salim H, Samad A, Qureshi N, Ng CJ. Is family history still underutilised? Exploring the views and experiences of primary care doctors in Malaysia. J Community Genet 2020; 11:413-420. [PMID: 32666196 PMCID: PMC7475133 DOI: 10.1007/s12687-020-00476-2] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2020] [Accepted: 07/08/2020] [Indexed: 12/15/2022] Open
Abstract
Family history has long been recognised as a non-invasive and inexpensive tool to identify individuals at risk of genetic conditions. Even in the era of evolving genetic and genomic technology, the role of family history in predicting individual risk for genetic testing and guiding in preventive interventions is still relevant, especially in low-resource countries. The aim of this study was to explore primary care doctors' views and experiences in family history taking and how they utilised family history in day-to-day clinical consultations in Malaysia. Four focus group discussions and six in-depth interviews involving 25 primary care doctors were conducted. Three themes emerged from the analysis: (1) primary care doctors considered family history as an important part of clinical assessment, (2) proactive versus reactive approach in collecting family history and (3) family history collection was variable and challenging. Family history was documented in either free text or pedigree depending on the perception of its appropriateness during the consultation. This study highlighted the need to improve the approach, documentation and the implementation of family history in the Malaysian primary care settings. Integrating family filing concept with built-in clinical decision support into electronic medical records is a potential solution in ensuring effective family history taking in primary care.
Collapse
Affiliation(s)
- Norita Hussein
- Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia.
| | - Tun Firzara Abdul Malik
- Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| | - Hani Salim
- Department of Family Medicine, Faculty of Medicine and Health Sciences, Universiti Putra Malaysia, Seri Kembangan, Selangor, Malaysia
| | - Azah Samad
- Section 7 Health Clinic, Ministry of Health, Shah Alam, Selangor, Malaysia
| | - Nadeem Qureshi
- Division of Primary Care, School of Medicine, University of Nottingham, Nottingham, NG7 2RD, UK
| | - Chirk Jenn Ng
- Department of Primary Care Medicine, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia
| |
Collapse
|
11
|
Mensah KB, Mensah ABB. Cancer control in Ghana: A narrative review in global context. Heliyon 2020; 6:e04564. [PMID: 32775744 PMCID: PMC7404540 DOI: 10.1016/j.heliyon.2020.e04564] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/13/2019] [Revised: 09/21/2019] [Accepted: 07/23/2020] [Indexed: 12/12/2022] Open
Abstract
Globally, cancer is likely to be ranked as the leading cause of death among non-communicable diseases in the 21st century. In Ghana, estimates suggest that the disease is expected to increase continuously. The best way to address the increasing burden is through a comprehensive cancer control program. This paper presents an appraisal of the literature, reports and, studies that seek to highlight strategies for cancer control globally and in Ghana. In consideration of literature, a search of relevant databases (PubMed, Google Scholar, Cochrane Database of Systematic Reviews, Google, International organizations web pages, International reports, Ministry of Health of Ghana reports, and textbooks) was performed. A narrative review of the background information on this subject is provided to inform future research on cancer control. This review was conducted as part of a study to involve community pharmacists in cancer detection and prevention in Ghana.
Collapse
Affiliation(s)
- Kofi Boamah Mensah
- Department of Pharmacy Practice, Faculty of Pharmacy & Pharmaceutical Science, College of Health Science, Kwame Nkrumah University of Science & Technology, Ghana
- University of KwaZulu-Natal, Discipline of Pharmaceutical Sciences, College of Health Sciences, Westville Campus, University Road, Durban, South Africa
| | - Adwoa Bemah Boamah Mensah
- Department of Nursing, College of Health Science, Kwame Nkrumah University of Science & Technology, Ghana
| |
Collapse
|
12
|
Kamaraju S, Drope J, Sankaranarayanan R, Shastri S. Cancer Prevention in Low-Resource Countries: An Overview of the Opportunity. Am Soc Clin Oncol Educ Book 2020; 40:1-12. [PMID: 32239989 PMCID: PMC7935443 DOI: 10.1200/edbk_280625] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
Abstract
Rising trends in the incidence of cancer in low- and middle-income countries (LMICs) add to the existing challenges with communicable and noncommunicable diseases. While breast and colorectal cancer incidence rates are increasing in LMICs, the incidence of cervical cancer shows a mixed trend, with rising incidence rates in China and sub-Saharan Africa and declining trends in the Indian subcontinent and South America. The increasing frequencies of unhealthy lifestyles, notably less physical activity, obesity, tobacco use, and alcohol consumption are causing a threat to health care in LMICs. Also, poorly developed health systems tend to have inadequate resources to implement early detection and adequate basic treatment. Inequalities in social determinants of health, lack of awareness of cancer and preventive care, lack of efficient referral pathways and patient navigation, and nonexistent or inadequate health care funding can lead to advanced disease presentation at diagnosis. This article provides an overview of opportunities to address cancer control in LMICs, with a focus on tobacco control, vaccination for cervical cancer, novel tools to assist with early detection, and screening for breast and other cancers.
Collapse
|
13
|
Ghassemi P, Ren X, Foster BM, Kerr BA, Agah M. Post-enrichment circulating tumor cell detection and enumeration via deformability impedance cytometry. Biosens Bioelectron 2020; 150:111868. [PMID: 31767345 PMCID: PMC6957725 DOI: 10.1016/j.bios.2019.111868] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2019] [Revised: 11/07/2019] [Accepted: 11/08/2019] [Indexed: 02/05/2023]
Abstract
Circulating tumor cells (CTCs) in blood can provide valuable information when detecting, diagnosing, and monitoring cancer. This paper describes a system that consists of a constriction-based microfluidic sensor with embedded electrodes that can detect and enumerate cancer cells in blood. The biosensor measures impedance in terms of magnitude and phase at multiple frequencies as cells transit through the constriction channel. Cancer cells deform as they move through while blood cells remain intact, thus generating differential impedance profiles that can be used for detecting and counting CTCs. Two versions of this device are reported, one where the electrodes are embedded into the disposable microfluidic channel, and the other in which the disposable chip is externally fixed to a reusable substrate housing the electrodes. Both configurations were tested by spiking breast or prostate cancer cells into murine blood, and both detected all tumor cells passing through the narrow channels while being able to differentiate between the two cell lines. The chip in its current format has a throughput of 1 μL/min. While the throughput is scalable by integrating more constriction channels in parallel, the presented assay is intended for post-enrichment label-free enumeration and characterization of CTCs.
Collapse
Affiliation(s)
- Parham Ghassemi
- The Bradley Department of Electrical and Computer Engineering, Virginia Tech, Blacksburg, VA, 24061, United States.
| | - Xiang Ren
- The Bradley Department of Electrical and Computer Engineering, Virginia Tech, Blacksburg, VA, 24061, United States.
| | - Brittni M Foster
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, United States.
| | - Bethany A Kerr
- Department of Cancer Biology, Wake Forest University School of Medicine, Winston-Salem, NC, 27157, United States.
| | - Masoud Agah
- The Bradley Department of Electrical and Computer Engineering, Virginia Tech, Blacksburg, VA, 24061, United States.
| |
Collapse
|
14
|
Adams SA, Haynes VE, Brandt HM, Choi SK, Young V, Eberth JM, Hébert JR, Friedman DB. Cervical cancer screening behaviors and proximity to federally qualified health centers in South Carolina. Cancer Epidemiol 2020; 65:101681. [PMID: 32035294 DOI: 10.1016/j.canep.2020.101681] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2019] [Revised: 12/18/2019] [Accepted: 01/28/2020] [Indexed: 11/28/2022]
Abstract
INTRODUCTION Lack of participation in cervical cancer screening in underserved populations has been attributed to access to care, particularly among women in rural areas. Federally Qualified Health Centers (FQHCs) were created to address this need in medically underserved populations. This study observed proximity to three health centers in relation to cervical cancer screening rates in South Carolina. METHODS Data were obtained from FQHC patient visits (from 3 centers) between 2007-2010 and were limited to women eligible for cervical cancer screening (n = 24,393). ArcGIS was used to geocode patients addresses and FQHC locations, and distance was calculated. Modified Poisson regression was used to estimate relative risk of obtaining cervical cancer screening within one yearor ever, stratified by residential area. RESULTS Findings differed markedly by center and urban/rural status. At two health clinics, rural residents living the furthest away from the clinic (∼9 miles difference between quartile 4 and quartile 1) were more likely to be ever screened (RRs = 1.05 and 1.03, p-values < 0.05), while urban residents living the furthest away were less likely to be ever screened (RR = 0.85, p-value < 0.05). At the third center, only urban residents living the furthest away were more likely to be ever screened (RR = 1.02, p-value < 0.05). CONCLUSIONS Increased travel distance significantly increased the likelihood of cervical cancer screening at two FQHC sites while significantly decreasing the likelihood of screening at the 3rd site. These findings underscore the importance of contextual and environmental factors that impact use of cervical cancer screening services.
Collapse
Affiliation(s)
- Swann Arp Adams
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; College of Nursing, University of South Carolina, 1601 Greene Street Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| | - Venice E Haynes
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| | - Heather M Brandt
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| | - Seul Ki Choi
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States; Department of Health Care Policy Research, Korea Institute for Health and Social Affairs, South Korea.
| | - Vicki Young
- South Carolina Primary Care Association, 3 Technology Circle Columbia, SC, 29203, United States.
| | - Jan M Eberth
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| | - James R Hébert
- Department of Epidemiology and Biostatistics, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| | - Daniela B Friedman
- Department of Health Promotion, Education, and Behavior, Arnold School of Public Health, University of South Carolina, 915 Greene Street, Columbia, SC, 29208, United States; Statewide Cancer Prevention and Control Program, University of South Carolina, 915 Greene Street Columbia, SC, 29208, United States.
| |
Collapse
|
15
|
Speiser D, Rebitschek FG, Feufel MA, Brand H, Besch L, Kendel F. Accuracy in risk understanding among BRCA1/2-mutation carriers. PATIENT EDUCATION AND COUNSELING 2019; 102:1925-1931. [PMID: 31079956 DOI: 10.1016/j.pec.2019.05.007] [Citation(s) in RCA: 11] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2018] [Revised: 03/07/2019] [Accepted: 05/04/2019] [Indexed: 06/09/2023]
Abstract
OBJECTIVE BRCA1/2-mutation carriers are at high risk of developing cancer. Since they must weigh clinical recommendations and decide on risk-reducing measures, the correct understanding of their 10-year cancer risks is essential. This study focused on the accuracy of women's subjective estimates of developing breast and ovarian cancer within ten years as prerequisite to reduce unnecessary prevention. METHODS 59 and 52 BRCA1/2-mutation carriers provided their individual risks of developing breast or ovarian cancer in the next 10 years, along with self-reported sociodemographic and psychosocial variables. Women's risk estimates were compared with their objective cancer risks that had been communicated before. RESULTS 22.6% of counselees under- and 53.2% of the counselees overestimated their 10-year risk of developing breast cancer. As for ovarian cancer, 5.6% under- whereas 51.9% overestimated their risk. Neither demographic factors such as education, parenthood and age, nor a prior diagnosis of breast cancer or prophylactic surgery accounted for these variations in risk accuracy. CONCLUSION Currently, risk communication during genetic counseling does not guarantee accurate risk estimation in BRCA-mutation carriers. PRACTICE IMPLICATIONS Counselors must be prepared to prevent overestimation. Counselees' risk estimates need to be assessed and corrected to enable informed decision-making and reduce risks of unnecessary preventive efforts.
Collapse
Affiliation(s)
- Dorothee Speiser
- Department of Gynecology with Breast Center, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
| | - Felix G Rebitschek
- Harding Center for Risk Literacy, Max Planck Institute for Human Development, Berlin, Lentzeallee 94, 14195 Berlin, Germany.
| | - Markus A Feufel
- Harding Center for Risk Literacy, Max Planck Institute for Human Development, Berlin, Lentzeallee 94, 14195 Berlin, Germany; Division of Ergonomics, Department of Psychology and Ergonomics, Technische Universität Berlin, Marchstr. 23, 10587 Berlin, Germany.
| | - Hannah Brand
- Institute of Medical Psychology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
| | - Laura Besch
- Institute of Medical Psychology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany
| | - Friederike Kendel
- Institute of Medical Psychology, Charité - Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
| |
Collapse
|
16
|
Liu B, Parsons V, Feuer EJ, Pan Q, Town M, Raghunathan TE, Schenker N, Xie D. Small Area Estimation of Cancer Risk Factors and Screening Behaviors in US Counties by Combining Two Large National Health Surveys. Prev Chronic Dis 2019; 16:E119. [PMID: 31469068 PMCID: PMC6716412 DOI: 10.5888/pcd16.190013] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
Background National health surveys, such as the National Health Interview Survey (NHIS) and the Behavioral Risk Factor Surveillance System (BRFSS), collect data on cancer screening and smoking-related measures in the US noninstitutionalized population. These surveys are designed to produce reliable estimates at the national and state levels. However, county-level data are often needed for cancer surveillance and related research. Methods To use the large sample sizes of BRFSS and the high response rates and better coverage of NHIS, we applied multilevel models that combined information from both surveys. We also used relevant sources such as census and administrative records. By using these methods, we generated estimates for several cancer risk factors and screening behaviors that are more precise than design-based estimates. Results We produced reliable, modeled estimates for 11 outcomes related to smoking and to screening for female breast cancer, cervical cancer, and colorectal cancer. The estimates were produced for 3,112 counties in the United States for the data period from 2008 through 2010. Conclusion The modeled estimates corrected for potential noncoverage bias and nonresponse bias in the BRFSS and reduced the variability in NHIS estimates that is attributable to small sample size. The small area estimates produced in this study can serve as a useful resource to the cancer surveillance community.
Collapse
Affiliation(s)
- Benmei Liu
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland.,Statistical Research and Applications Branch, Division of Cancer Control and Population Sciences, National Cancer Institute, 9609 Medical Center Drive, MSC 9765, Bethesda, MD 20892.
| | - Van Parsons
- National Center for Health Statistics, Centers for Disease Control and Prevention, Hyattsville, Maryland
| | - Eric J Feuer
- Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, Maryland
| | - Qiang Pan
- Harbin Institute of Technology, Shenzhen, Guangdong, China
| | - Machell Town
- Division of Population Health, Centers for Disease Control and Prevention, Atlanta, Georgia
| | - Trivellore E Raghunathan
- Department of Biostatistics and Institute for Social Research, University of Michigan, Ann Arbor, Michigan
| | - Nathaniel Schenker
- National Center for Health Statistics (retired), Centers for Disease Control and Prevention, Hyattsville, Maryland
| | - Dawei Xie
- Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania
| |
Collapse
|
17
|
Brinton JT, Hendrick RE, Ringham BM, Kriege M, Glueck DH. Improving the diagnostic accuracy of a stratified screening strategy by identifying the optimal risk cutoff. Cancer Causes Control 2019; 30:1145-1155. [PMID: 31377875 DOI: 10.1007/s10552-019-01208-9] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/10/2018] [Accepted: 06/29/2019] [Indexed: 12/29/2022]
Abstract
BACKGROUND The American Cancer Society (ACS) suggests using a stratified strategy for breast cancer screening. The strategy includes assessing risk of breast cancer, screening women at high risk with both MRI and mammography, and screening women at low risk with mammography alone. The ACS chose their cutoff for high risk using expert consensus. METHODS We propose instead an analytic approach that maximizes the diagnostic accuracy (AUC/ROC) of a risk-based stratified screening strategy in a population. The inputs are the joint distribution of screening test scores, and the odds of disease, for the given risk score. Using the approach for breast cancer screening, we estimated the optimal risk cutoff for two different risk models: the Breast Cancer Screening Consortium (BCSC) model and a hypothetical model with much better discriminatory accuracy. Data on mammography and MRI test score distributions were drawn from the Magnetic Resonance Imaging Screening Study Group. RESULTS A risk model with an excellent discriminatory accuracy (c-statistic [Formula: see text]) yielded a reasonable cutoff where only about 20% of women had dual screening. However, the BCSC risk model (c-statistic [Formula: see text]) lacked the discriminatory accuracy to differentiate between women who needed dual screening, and women who needed only mammography. CONCLUSION Our research provides a general approach to optimize the diagnostic accuracy of a stratified screening strategy in a population, and to assess whether risk models are sufficiently accurate to guide stratified screening. For breast cancer, most risk models lack enough discriminatory accuracy to make stratified screening a reasonable recommendation.
Collapse
Affiliation(s)
- John T Brinton
- Department of Biostatistics and Informatics, Colorado School of Public Health, Aurora, CO, USA. .,Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA.
| | - R Edward Hendrick
- Department of Radiology, School of Medicine, University of Colorado Denver, Aurora, CO, USA
| | - Brandy M Ringham
- Lifecourse Epidemiology of Adiposity and Diabetes (LEAD) Center, University of Colorado Denver, Aurora, CO, USA
| | - Mieke Kriege
- Department of Medical Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands
| | - Deborah H Glueck
- Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO, USA
| |
Collapse
|
18
|
Khayeka-Wandabwa C, Ma X, Cao X, Nunna V, Pathak JL, Bernhardt R, Cai P, Bureik M. Plasma membrane localization of CYP4Z1 and CYP19A1 and the detection of anti-CYP19A1 autoantibodies in humans. Int Immunopharmacol 2019; 73:64-71. [PMID: 31082724 DOI: 10.1016/j.intimp.2019.05.003] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2019] [Revised: 04/14/2019] [Accepted: 05/02/2019] [Indexed: 12/15/2022]
Abstract
It is thought that autoantibody (aAb) production can be caused by (aberrant) protein targeting to the plasma surface of cells. We recently demonstrated the presence of the human cytochrome P450 enzyme CYP4Z1 on the plasma membrane of MCF-7 breast cancer cells and the detection of high titers of anti-CYP4Z1 aAbs in breast cancer patients, but not in healthy controls. In the present study we show that cells of the normal breast cell line MCF-10A do not display CYP4Z1 on their surface. By contrast, we detected CYP19A1 (aromatase) on the plasma membrane of both cell lines. Interestingly, the presence of CYPs on the cell surface did not correlate with their relative expression levels in these cell lines. Indirect ELISA experiments demonstrated the presence of anti-CYP19A1 aAbs in female breast cancer patient sera as well as in male and female controls, respectively; aAb titers in all three groups varied considerably and overall, the results obtained for each group were not significantly different from those of either of the other two groups. Based on these data we propose the hypothesis that CYP translocation to the plasma membrane, but not the intracellular expression level, is the crucial precondition for the generation of anti-CYP aAbs.
Collapse
Affiliation(s)
- Christopher Khayeka-Wandabwa
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China
| | - Xiaoshuang Ma
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China
| | - Xiaolin Cao
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China
| | - Venkatrao Nunna
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China
| | - Janak L Pathak
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China
| | - Rita Bernhardt
- Institute of Biochemistry, Saarland University, Saarbruecken, Germany
| | - Pengcheng Cai
- Department of Clinical Laboratory, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
| | - Matthias Bureik
- School of Pharmaceutical Science and Technology (SPST), Health Science Platform, Tianjin University, Tianjin, China.
| |
Collapse
|
19
|
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Wender RC. Cancer screening in the United States, 2019: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2019; 69:184-210. [PMID: 30875085 DOI: 10.3322/caac.21557] [Citation(s) in RCA: 376] [Impact Index Per Article: 75.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, the current American Cancer Society cancer screening guidelines are summarized, and the most current data from the National Health Interview Survey are provided on the utilization of cancer screening for men and women and on the adherence of men and women to multiple recommended screening tests.
Collapse
Affiliation(s)
- Robert A Smith
- Vice-President, Cancer Screening, and Director, Center for Quality Cancer Screening and Research, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Kimberly S Andrews
- Director, Guidelines Process, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Durado Brooks
- Vice President, Cancer Control Interventions, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Stacey A Fedewa
- Senior Principal Scientist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA
| | | | - Debbie Saslow
- Senior Director, Human Papillomavirus-Related and Women's Cancers, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Richard C Wender
- Chief Cancer Control Officer, American Cancer Society, Atlanta, GA
| |
Collapse
|
20
|
Wang W, Jin J, Dai F, Long Z, Liu X, Cai H, Zhou Y, Chen Z, Huang H. Interleukin-15 suppresses gastric cancer liver metastases by enhancing natural killer cell activity in a murine model. Oncol Lett 2018; 16:4839-4846. [PMID: 30250549 PMCID: PMC6144747 DOI: 10.3892/ol.2018.9303] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2015] [Accepted: 04/28/2017] [Indexed: 12/12/2022] Open
Abstract
Interleukin (IL)-15 is a promising cytokine for cancer immunotherapy as it is a critical factor for the proliferation and activation of natural killer (NK) cells. Previous studies have suggested critical roles of IL-15 in tumor invasion and metastasis. However, the association between IL-15 and liver metastasis of gastric cancer (LMGC) remains unknown. The present study investigated the therapeutic efficacy of recombinant mouse IL-15 (rmIL-15) in murine LMGC models, in which stable green fluorescent protein (GFP)-expressing MKN45 cells (MKN45-GFP cells) were injected into the spleen parenchyma of mice for liver metastasis. At different treatments (high dose group: 2.5 µg of rmIL-15; low dose group: 0.2 µg of rmIL-15; control group: PBS), it was found that rmIL-15 decreased the formation of liver metastasis sites. Additionally, this treatment lead to improved survival of mice following tumor cell transplantation. Treatment with a high dose of rmIL-15 provided greater therapeutic efficacy by prolonged survival of the mice compared with low dose group and control group. It was found that NK cells isolated from the liver that received the high dose of rmIL-15 showed stronger cytotoxic activity compared with the other two groups on the target cells. These findings hold significant importance for the use of IL-15 as a potential adjuvant/therapeutic for liver metastasis from gastric cancer.
Collapse
Affiliation(s)
- Wei Wang
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China.,Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China
| | - Jiejie Jin
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| | - Faxiang Dai
- Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China
| | - Ziwen Long
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| | - Xiaowen Liu
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| | - Hong Cai
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| | - Ye Zhou
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| | - Zhong Chen
- Department of Hepatobiliary Surgery, Affiliated Hospital of Nantong University, Nantong, Jiangsu 226000, P.R. China
| | - Hua Huang
- Department of Gastric Cancer and Soft Tissue Sarcoma, Fudan University Shanghai Cancer Center, Shanghai 200032, P.R. China.,Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, P.R. China
| |
Collapse
|
21
|
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2018; 68:297-316. [PMID: 29846940 DOI: 10.3322/caac.21446] [Citation(s) in RCA: 340] [Impact Index Per Article: 56.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2017] [Accepted: 12/19/2017] [Indexed: 02/06/2023] Open
Abstract
Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates from the National Health Interview Survey, and select issues related to cancer screening. In this 2018 update, we also summarize the new American Cancer Society colorectal cancer screening guideline and include a clarification in the language of the 2013 lung cancer screening guideline. CA Cancer J Clin 2018;68:297-316. © 2018 American Cancer Society.
Collapse
Affiliation(s)
- Robert A Smith
- Vice President, Cancer Screening, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Kimberly S Andrews
- Director, Guidelines Process, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Durado Brooks
- Vice President, Cancer Control Interventions, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Stacey A Fedewa
- Strategic Director for Risk Factors & Screening Surveillance, Department of Epidemiology and Research Surveillance, American Cancer Society, Atlanta, GA
| | | | - Debbie Saslow
- Senior Director, HPV Related and Women's Cancers, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Otis W Brawley
- Chief Medical Officer, American Cancer Society, Atlanta, GA
| | - Richard C Wender
- Chief Cancer Control Officer, American Cancer Society, Atlanta, GA
| |
Collapse
|
22
|
Migowski A, Dias MBK, Nadanovsky P, Silva GAE, Sant'Ana DR, Stein AT. Guidelines for early detection of breast cancer in Brazil. III - Challenges for implementation. CAD SAUDE PUBLICA 2018; 34:e00046317. [PMID: 29952397 DOI: 10.1590/0102-311x00046317] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/20/2017] [Accepted: 02/23/2018] [Indexed: 12/22/2022] Open
Abstract
The objective of the current article is to present the main challenges for the implementation of the new recommendations for early detection of breast cancer in Brazil, and to reflect on the barriers and the strategies to overcome them. The implementation of evidence-based guidelines is a global challenge, and traditional strategies based only on disseminating their recommendations have proven insufficient for changing prevailing clinical practice. A major challenge for adherence to the new guidelines for early detection of breast cancer in Brazil is the current pattern in the use of mammographic screening in the country, which very often includes young women and a short interval between tests. Such practice, harmful to the population's health, is reinforced by the logic of defensive medicine and the dissemination of erroneous information that overestimates the benefits of screening and underestimates or even omits its harms. In addition, there is a lack of policies and measures focused on early diagnosis of symptomatic cases. To overcome these barriers, changes in the regulation of care, financing, and implementation of shared decision-making in primary care are essential. Audit and feedback, academic detailing, and the incorporation of decision aids are some of the strategies that can facilitate implementation of the new recommendations.
Collapse
Affiliation(s)
- Arn Migowski
- Instituto Nacional de Câncer José Alencar Gomes da Silva, Rio de Janeiro, Brasil.,Instituto Nacional de Cardiologia, Rio de Janeiro, Brasil
| | | | - Paulo Nadanovsky
- Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil.,Escola Nacional de Saúde Pública Sergio Arouca, Fundação Oswaldo Cruz, Rio de Janeiro, Brasil
| | - Gulnar Azevedo E Silva
- Instituto de Medicina Social, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brasil
| | | | | |
Collapse
|
23
|
Qin SH, Li XM, Li WL. [Influencing factors on the quality of life and medical coping style of patients with oral cancer]. HUA XI KOU QIANG YI XUE ZA ZHI = HUAXI KOUQIANG YIXUE ZAZHI = WEST CHINA JOURNAL OF STOMATOLOGY 2018; 36:271-276. [PMID: 29984927 PMCID: PMC7030301 DOI: 10.7518/hxkq.2018.03.008] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Received: 09/04/2017] [Revised: 11/15/2017] [Indexed: 11/21/2022]
Abstract
OBJECTIVE To evaluate the influencing factors on the postoperative quality of life and to analyze the coping styles of patients with oral cancer. METHODS A total of 131 oral cancer cases confirmed through diagnostic criteria were investigated to analyze the influencing factors on the quality of life (QOL) and the relationship between coping style and QOL of these patients by using the fourth edition of the University of Washington Quality of Life Questionnaire (UWQOL) and medical coping modes questionnaires (MCMQ), respectively. RESULTS Among the 131 questionnaires collected, only 126 were valid with a recovery rate of 96.18% (126/131). Single factor analysis showed that age, marital status, educational level, other systemic diseases, personal income level, tooth loss, operation times, adjuvant radiotherapy, cancer staging, cervical lymph node dissection, recurrence, and jaw resection yielded different UWQOL scale scores (P<0.05). Multiple regression analysis showed that the loss of teeth, cancer staging, recurrence, and jaw resection yielded statistically significant differences in the total score of UWQOL (P<0.05). Among the coping styles, the average scores of "confrontation", "avoidance", and "yielding" were 17.54±4.97, 17.79±2.19, and 12.97±5.70, respectively. Compared with the norm, the difference was statistically significant (P<0.05). Correlation analysis showed that "confrontation" and "avoidance" were positively correlated, whereas "yielding" was negatively correlated to QOL (P<0.05). CONCLUSIONS Age, marital status, educational level, other systemic diseases, personal income level, tooth loss, operation times, adjuvant radiotherapy, cancer staging, cervical lymph node dissection, recurrence, and jaw resection have different effects on the quality of QOL. Tooth loss, cancer staging, recurrence, and jaw resection are the main causative factors affecting the patients' perceived QOL. Personalized treatment and nursing care should be strengthened to improve the coping style and quality of life of patients.
Collapse
Affiliation(s)
- Shuai-Hua Qin
- Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Xin-Ming Li
- Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| | - Wen-Lu Li
- Dept. of Oral and Maxillofacial Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China
| |
Collapse
|
24
|
Hu X, Jiang L, Li Q, Gu Y. Quantitative assessment of background parenchymal enhancement in breast magnetic resonance images predicts the risk of breast cancer. Oncotarget 2018; 8:10620-10627. [PMID: 27895314 PMCID: PMC5354686 DOI: 10.18632/oncotarget.13538] [Citation(s) in RCA: 26] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2016] [Accepted: 11/01/2016] [Indexed: 12/21/2022] Open
Abstract
The objective of this study was to evaluate the association betweenthe quantitative assessment of background parenchymal enhancement rate (BPER) and breast cancer. From 14,033 consecutive patients who underwent breast MRI in our center, we randomly selected 101 normal controls. Then, we selected 101 women with benign breast lesions and 101 women with breast cancer who were matched for age and menstruation status. We evaluated BPER at early (2 minutes), medium (4 minutes) and late (6 minutes) enhanced time phases of breast MRI for quantitative assessment. Odds ratios (ORs) for risk of breast cancer were calculated using the receiver operating curve. The BPER increased in a time-dependent manner after enhancement in both premenopausal and postmenopausal women. Premenopausal women had higher BPER than postmenopausal women at early, medium and late enhanced phases. In the normal population, the OR for probability of breast cancer for premenopausal women with high BPER was 4.1 (95% CI: 1.7–9.7) and 4.6 (95% CI: 1.7–12.0) for postmenopausal women. The OR of breast cancer morbidity in premenopausal women with high BPER was 2.6 (95% CI: 1.1–6.4) and 2.8 (95% CI: 1.2–6.1) for postmenopausal women. The BPER was found to be a predictive factor of breast cancer morbidity. Different time phases should be used to assess BPER in premenopausal and postmenopausal women.
Collapse
Affiliation(s)
- Xiaoxin Hu
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
| | - Luan Jiang
- Center for Advanced Medical Imaging Technology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China
| | - Qiang Li
- Center for Advanced Medical Imaging Technology, Shanghai Advanced Research Institute, Chinese Academy of Sciences, Shanghai, China
| | - Yajia Gu
- Department of Radiology, Fudan University Shanghai Cancer Center, Shanghai, China.,Department of Oncology, Fudan University Shanghai Medical College, Shanghai, China
| |
Collapse
|
25
|
Spina M, Arndt J, Landau MJ, Cameron LD. Enhancing Health Message Framing With Metaphor and Cultural Values: Impact on Latinas' Cervical Cancer Screening. Ann Behav Med 2018; 52:106-115. [PMID: 29538628 PMCID: PMC6361230 DOI: 10.1093/abm/kax009] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
Background An integration of message framing and sociocultural literature suggests that ethnic health disparities may be reduced by incorporating minority groups' cultural values into persuasive health messages. Framing messages with metaphors represents one promising strategy for harnessing cultural values to change health outcomes. Still, the effectiveness of metaphoric health messages in minority populations has received virtually no empirical attention. Purpose To fill this gap, the present study tested whether a health message using a cancer-screening metaphor targeting collectivism and familism values would engage individual differences in these values to predict Papanicolaou (Pap) smear intentions among Latinas. Methods Latina women (N = 168) completed an online survey including measures of collectivism and familism. They were randomized to read a message about Pap smears featuring the metaphor the body is a family or no metaphor before reporting their Pap smear intentions. Results Regression analyses revealed a pattern of interactions suggesting metaphoric messages engage targeted cultural values: For Latinas reading the family metaphor message, collectivism and familism positively predicted Pap smear intentions, whereas for Latinas reading the no-metaphor message, these values did not predict intentions. Conclusions This study offers a foundation for further examination of the potential for metaphoric health messages that connect to cultural values to reduce ethnic health disparities. Implications and directions for future research are discussed.
Collapse
Affiliation(s)
- Melissa Spina
- Department of Counseling, San Francisco State University, CA, USA
| | - Jamie Arndt
- Department of Psychological Sciences, University of Missouri, MO, USA
| | - Mark J Landau
- Department of Psychology, University of Kansas, KS, USA
| | - Linda D Cameron
- Psychological Sciences, University of California Merced, CA, USA
| |
Collapse
|
26
|
Jin XY, Zhang KP, Chen H, Miao TT, Wang SF, Gu W. Synthesis, in vitro Antimicrobial, and Cytotoxic Activities of New 1,3,4-Oxadiazin-5(6H
)-one Derivatives from Dehydroabietic Acid. J CHIN CHEM SOC-TAIP 2018. [DOI: 10.1002/jccs.201700358] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Affiliation(s)
- Xiao-Yan Jin
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| | - Kang-Ping Zhang
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| | - Hao Chen
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| | - Ting-Ting Miao
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| | - Shi-Fa Wang
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| | - Wen Gu
- Jiangsu Provincial Key Lab for the Chemistry and Utilization of Agro-forest Biomass, Jiangsu Key Lab of Biomass-based Green Fuels and Chemicals, College of Chemical Engineering; Nanjing Forestry University; Nanjing 210037 P. R. China
| |
Collapse
|
27
|
Molina Y, Pichardo CM, Patrick DL, Ramsey SD, Bishop S, Beresford SAA, Coronado GD. Estimating the costs and cost-effectiveness of promoting mammography screening among US-based Latinas. JOURNAL OF HEALTH DISPARITIES RESEARCH AND PRACTICE 2018; 12:10. [PMID: 34414017 PMCID: PMC8373201] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Abstract
PURPOSE We characterize the costs and cost-effectiveness of a community health worker (CHW)-based intervention to promote screening mammography among US-based non-adherent Latinas. METHODS The parent study was a randomized controlled trial for 536 Latinas aged 42-74 years old who had sought care within a safety net health center in Western Washington. Participants were block-randomized within clinic to the control arm (usual care) or intervention arm (CHW-led motivational interviewing intervention). We used the perspective of the organization implementing promotional activities to characterize costs and cost-effectiveness. Cost data were categorized as program set-up and maintenance (initial training, booster/annual training) program implementation (administrative activities, intervention delivery); and, overhead/miscellaneous expenses. Cost-effectiveness was calculated as the incremental cost of screening for each additional woman screened between the intervention and control arms. RESULTS The respective costs per participant for standard care and the intervention arm were $69.96 and $300.99. There were no study arm differences in 1-year QALYs were small among women who completed a 12-month follow-up survey (intervention= 0.8827, standard care = 0.8841). Most costs pertained to program implementation and administrative activities specifically. The incremental cost per additional woman screened was $2,595.32. CONCLUSIONS Our findings are within the ranges of costs and cost-effectiveness for other CHW programs to promote screening mammography among underserved populations. Our strong study design and focus on non-adherent women provides important strengths to this body of work, especially give implementation and dissemination science efforts regarding CHW-based health promotion for health disparity populations.
Collapse
Affiliation(s)
| | | | - Donald L Patrick
- University of Washington and the Fred Hutchinson Cancer Research Center
| | - Scott D Ramsey
- University of Washington and the Fred Hutchinson Cancer Research
| | - Sonia Bishop
- University of Washington and the Fred Hutchinson Cancer Research
| | | | | |
Collapse
|
28
|
The role of F18-FDG PET/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer. Surg Oncol 2017; 26:347-351. [DOI: 10.1016/j.suronc.2017.07.004] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2017] [Revised: 07/04/2017] [Accepted: 07/13/2017] [Indexed: 11/24/2022]
|
29
|
Niell BL, Freer PE, Weinfurtner RJ, Arleo EK, Drukteinis JS. Screening for Breast Cancer. Radiol Clin North Am 2017; 55:1145-1162. [DOI: 10.1016/j.rcl.2017.06.004] [Citation(s) in RCA: 65] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
30
|
Oba S, Toyoshima M, Ogata H. Association of Cervical Cancer Screening with Knowledge of Risk Factors, Access to Health Related Information, Health Profiles, and Health Competence Beliefs among Community-Dwelling Women in Japan. Asian Pac J Cancer Prev 2017; 18:2115-2121. [PMID: 28843231 PMCID: PMC5697469 DOI: 10.22034/apjcp.2017.18.8.2115] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/14/2022] Open
Abstract
Objective: The aim of this study was to evaluate the past attendance for cervical cancer screening with knowledge
of risk factors, access to health-related information, health profiles and health competence beliefs among Japanese
women. Methods: Women ages 25, 30, 35, 40, 45, 50, 55, and 60 were contacted cross-sectionally as part of a project
for the Japanese Ministry of Health, Labour and Welfare in Nikaho, Akita prefecture Japan between June 2010 and
March 2011, and 249 women were analyzed for the current study. The questionnaire asked about past cervical cancer
screening. Knowledge of each cervical cancer risk factor was determined on a four-point scale. A barriers to information
access scale was utilized to assess the degree of difficulty in accessing health-related information. Health profiles were
measured using the EuroQOL EQ-5D. Perceived health competence was measured using a scale (PHCS). The association
was evaluated with odds ratios with 95% confidence interval were calculated from a logistic regression analysis after
adjustment for age and potential confounders. The trend across the level was also assessed. Results: Women who knew
that sexual intercourse at young age was a risk factor were significantly more likely to have participated in cervical
cancer screening sometime in their lives (p for trend =0.02). Women who had pain/discomfort and those who had
anxiety/depression were significantly more likely to have participated in cervical screening within the past two years
(odds ratio [OR]: 2.02, 95% confidence interval [CI]: 1.04–3.94; OR: 2.32, 95% CI: 1.05–5.16, respectively). Women
with higher PHCS were significantly more likely to have attended for cervical screened at some point in their lives
(p=0.04). Conclusion: This study observed that specific knowledge of cervical cancer risk factors, health profiles and
PHCS were associated with the past attendance for cervical cancer screening among women in a community. Further
researches are warranted.
Collapse
Affiliation(s)
- Shino Oba
- Graduate School of Health Sciences, Gunma University, 3-39-22 Showa-machi, Maebashi, Gunma, Japan.
| | | | | |
Collapse
|
31
|
Ou C, Sun Z, Li S, Li G, Li X, Ma J. Dual roles of yes-associated protein (YAP) in colorectal cancer. Oncotarget 2017; 8:75727-75741. [PMID: 29088905 PMCID: PMC5650460 DOI: 10.18632/oncotarget.20155] [Citation(s) in RCA: 40] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2017] [Accepted: 07/30/2017] [Indexed: 02/07/2023] Open
Abstract
Yes-associated protein (YAP) is a downstream effector molecule of a newly emerging tumour suppressor pathway called the Hippo pathway. YAP is a transcriptional co-activator and mis-expressed in various cancers, including colorectal cancer (CRC). Accumulating studies show that the high expression of nuclear YAP is linked with tumour progression and decreased survival. Nuclear YAP can interact with other transcription factors to promote cancer cell proliferation, apoptosis, metastasis and maintenance of stemness. Therefore, YAP has the potential to be a tumour biomarker or therapeutic target for CRC. However, recently, a number of studies have supported a contradictory role for YAP as a tumour suppressor, demonstrating inhibition of the tumorigenesis of CRC, involvement in promoting cell apoptosis, and inhibiting the maintenance of intestinal stem cells and inflammatory activity. In these studies, high expression of YAP was highly correlated with worse survival in CRC. In this review, we will comprehensively summarize and analyse these paradoxical reports, and discuss both the oncogenic and tumour suppressor functions of YAP in the differential status of CRC progression. Further investigation into the mechanisms responsible for the dual function of YAP will be of great value in the prevention, early diagnosis, and therapy of CRC.
Collapse
Affiliation(s)
- Chunlin Ou
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.,Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan 410078, China.,Hunan Key Laboratory of Nonresolving Inflammation and Cancer, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Zhenqiang Sun
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.,Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan 410078, China.,Department of Anorectal Surgery, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450052, China.,Department of Gastrointestinal Surgery, Tumor Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830011, China
| | - Shen Li
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.,Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan 410078, China
| | - Guiyuan Li
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.,Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan 410078, China
| | - Xiayu Li
- Hunan Key Laboratory of Nonresolving Inflammation and Cancer, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| | - Jian Ma
- Hunan Cancer Hospital and the Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan 410013, China.,Key Laboratory of Carcinogenesis and Cancer Invasion of the Chinese Ministry of Education, Cancer Research Institute, Central South University, Changsha, Hunan 410078, China.,Hunan Key Laboratory of Nonresolving Inflammation and Cancer, The Third Xiangya Hospital, Central South University, Changsha, Hunan 410013, China
| |
Collapse
|
32
|
Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, Brawley OW, Wender RC. Cancer screening in the United States, 2017: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2017; 67:100-121. [PMID: 28170086 DOI: 10.3322/caac.21392] [Citation(s) in RCA: 278] [Impact Index Per Article: 39.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/19/2022] Open
Abstract
Answer questions and earn CME/CNE Each year, the American Cancer Society publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, the authors summarize current American Cancer Society cancer screening guidelines, describe an update of their guideline for using human papillomavirus vaccination for cancer prevention, describe updates in US Preventive Services Task Force recommendations for breast and colorectal cancer screening, discuss interim findings from the UK Collaborative Trial on Ovarian Cancer Screening, and provide the latest data on utilization of cancer screening from the National Health Interview Survey. CA Cancer J Clin 2017;67:100-121. © 2017 American Cancer Society.
Collapse
Affiliation(s)
- Robert A Smith
- Vice President, Cancer Screening, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Kimberly S Andrews
- Director, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Durado Brooks
- Managing Director, Cancer Control Intervention, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Stacey A Fedewa
- Director for Risk Factor Screening and Surveillance, Department of Epidemiology and Research Surveillance, American Cancer Society, Atlanta, GA
| | | | - Debbie Saslow
- Senior Director, HPV Related and Women's Cancer, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Otis W Brawley
- Chief Medical Officer, American Cancer Society, Atlanta, GA
| | - Richard C Wender
- Chief Cancer Control Officer, American Cancer Society, Atlanta, GA
| |
Collapse
|
33
|
Tang CK, Vaze A, Rusling JF. Automated 3D-printed unibody immunoarray for chemiluminescence detection of cancer biomarker proteins. LAB ON A CHIP 2017; 17:484-489. [PMID: 28067370 PMCID: PMC5317057 DOI: 10.1039/c6lc01238h] [Citation(s) in RCA: 42] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 05/06/2023]
Abstract
A low cost three-dimensional (3D) printed clear plastic microfluidic device was fabricated for fast, low cost automated protein detection. The unibody device features three reagent reservoirs, an efficient 3D network for passive mixing, and an optically transparent detection chamber housing a glass capture antibody array for measuring chemiluminescence output with a CCD camera. Sandwich type assays were built onto the glass arrays using a multi-labeled detection antibody-polyHRP (HRP = horseradish peroxidase). Total assay time was ∼30 min in a complete automated assay employing a programmable syringe pump so that the protocol required minimal operator intervention. The device was used for multiplexed detection of prostate cancer biomarker proteins prostate specific antigen (PSA) and platelet factor 4 (PF-4). Detection limits of 0.5 pg mL-1 were achieved for these proteins in diluted serum with log dynamic ranges of four orders of magnitude. Good accuracy vs. ELISA was validated by analyzing human serum samples. This prototype device holds good promise for further development as a point-of-care cancer diagnostics tool.
Collapse
Affiliation(s)
- C K Tang
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269-3060, USA.
| | - A Vaze
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269-3060, USA.
| | - J F Rusling
- Department of Chemistry, University of Connecticut, 55 North Eagleville Road, Storrs, Connecticut 06269-3060, USA. and Institute of Materials Science, University of Connecticut, Storrs, Connecticut 06269, USA and Dept. of Surgery, and Neag Cancer Center, UConn Health, 263 Farmington Av., Farmington, Connecticut 06030, USA and School of Chemistry, National University of Ireland at Galway, Ireland
| |
Collapse
|
34
|
Abstract
BACKGROUND Obtaining cancer screening on patients with limited life expectancy has been proposed as a measure for low quality care for primary care physicians (PCPs). However, administrative data may underestimate life expectancy in patients who undergo screening. OBJECTIVE To determine the association between receipt of screening mammography or PSA and overall survival. DESIGN Retrospective cohort study from 1/1/1999 to 12/31/2012. Receipt of screening was assessed for 2001-2002 and survival from 1/1/2003 to 12/31/2012. Life expectancy was estimated as of 1/1/03 using a validated algorithm, and was compared to actual survival for men and women, stratified by receipt of cancer screening. PARTICIPANTS A 5 % sample of Medicare beneficiaries aged 69-90 years as of 1/1/2003 (n = 906,723). INTERVENTIONS Receipt of screening mammography in 2001-2002 for women, or a screening PSA test in 2002 for men. MAIN MEASURES Survival from 1/1/2003 through 12/31/2012. KEY RESULTS Subjects were stratified by life expectancy based on age and comorbidity. Within each stratum, the subjects with prior cancer screening had actual median survivals higher than those who were not screened, with differences ranging from 1.7 to 2.1 years for women and 0.9 to 1.1 years for men. In a Cox model, non-receipt of screening in women had an impact on survival (HR = 1.52; 95 % CI = 1.51, 1.54) similar in magnitude to a diagnosis of complicated diabetes or heart failure, and was comparable to uncomplicated diabetes or liver disease in men (HR = 1.23; 1.22, 1.25). CONCLUSIONS Receipt of cancer screening is a powerful marker of health status that is not captured by comorbidity measures in administrative data. Because life expectancy algorithms using administrative data underestimate the life expectancy of patients who undergo screening, they can overestimate the problem of cancer screening in patients with limited life expectancy.
Collapse
Affiliation(s)
- James S Goodwin
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.
- Sealy Center on Aging, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0177, USA.
- Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA.
| | - Kristin Sheffield
- Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA
- Department of Preventive Medicine and Community Health, University of Texas Medical Branch, Galveston, TX, USA
- Global Patient Outcomes and Real World Evidence, Eli Lilly and Company, Indianapolis, IN, 46285, USA
| | - Shuang Li
- Sealy Center on Aging, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0177, USA
| | - Alai Tan
- Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA
- Sealy Center on Aging, University of Texas Medical Branch, 301 University Blvd, Galveston, TX, 77555-0177, USA
- Institute for Translational Sciences, University of Texas Medical Branch, Galveston, TX, USA
- Ohio State University School of Nursing, 1582 Neil Ave, Columbus, OH, 43210, USA
| |
Collapse
|
35
|
Owens OL, Friedman DB, Brandt HM, Bernhardt JM, Hébert JR. Digital Solutions for Informed Decision Making: An Academic-Community Partnership for the Development of a Prostate Cancer Decision Aid for African American Men. Am J Mens Health 2016; 10:207-19. [PMID: 25563381 PMCID: PMC4492917 DOI: 10.1177/1557988314564178] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
African American (AA) men are significantly more likely to die of prostate cancer (PrCA) than other racial groups, and there is a critical need to identify strategies for providing information about PrCA screening and the importance of informed decision making (IDM). To assess whether a computer-based IDM intervention for PrCA screening would be appropriate for AA men, this formative evaluation study examined their (1) PrCA risk and screening knowledge; (2) decision-making processes for PrCA screening; (3) usage of, attitudes toward, and access to interactive communication technologies (ICTs); and (4) perceptions regarding a future, novel, computer-based PrCA education intervention. A purposive convenience sample of 39 AA men aged 37 to 66 years in the Southeastern United States was recruited through faith-based organizations to participate in one of six 90-minute focus groups and complete a 45-item descriptive survey. Participants were generally knowledgeable about PrCA. However, few engaged in IDM with their doctor and few were informed about the associated risks and uncertainties of PrCA screening. Most participants used ICTs on a daily basis for various purposes including health information seeking. Most participants were open to a novel, computer-based intervention if the system was easy to use and its animated avatars were culturally appropriate. Because study participants had low exposure to IDM for PrCA, but frequently used ICTs, IDM interventions using ICTs (e.g., computers) hold promise for AA men and should be explored for feasibility and effectiveness. These interventions should aim to increase PrCA screening knowledge and stress the importance of participating in IDM with doctors.
Collapse
|
36
|
Smith RA, Andrews K, Brooks D, DeSantis CE, Fedewa SA, Lortet-Tieulent J, Manassaram-Baptiste D, Brawley OW, Wender RC. Cancer screening in the United States, 2016: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin 2016; 66:96-114. [PMID: 26797525 DOI: 10.3322/caac.21336] [Citation(s) in RCA: 169] [Impact Index Per Article: 21.1] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/23/2015] [Accepted: 11/23/2015] [Indexed: 12/11/2022] Open
Abstract
Each year the American Cancer Society (ACS) publishes a summary of its guidelines for early cancer detection, data and trends in cancer screening rates, and select issues related to cancer screening. In this issue of the journal, we summarize current ACS cancer screening guidelines, including the update of the breast cancer screening guideline, discuss quality issues in colorectal cancer screening and new developments in lung cancer screening, and provide the latest data on utilization of cancer screening from the National Health Interview Survey.
Collapse
Affiliation(s)
- Robert A Smith
- Vice President, Cancer Screening, Cancer Control Department, American Cancer Society Atlanta, GA
| | - Kimberly Andrews
- Director, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Durado Brooks
- Managing Director, Cancer Control Intervention, Cancer Control Department, American Cancer Society, Atlanta, GA
| | - Carol E DeSantis
- Senior Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA
| | - Stacey A Fedewa
- Director for Risk Factor Screening and Surveillance, Department of Epidemiology and Research Surveillance, American Cancer Society, Atlanta, GA
| | - Joannie Lortet-Tieulent
- Senior Epidemiologist, Surveillance and Health Services Research, American Cancer Society, Atlanta, GA
| | | | - Otis W Brawley
- Chief Medical Officer, American Cancer Society, Atlanta, GA
| | - Richard C Wender
- Chief Cancer Control Officer, American Cancer Society, Atlanta, GA
| |
Collapse
|
37
|
Mandelblatt JS, Stout NK, Schechter CB, van den Broek JJ, Miglioretti DL, Krapcho M, Trentham-Dietz A, Munoz D, Lee SJ, Berry DA, van Ravesteyn NT, Alagoz O, Kerlikowske K, Tosteson AN, Near AM, Hoeffken A, Chang Y, Heijnsdijk EA, Chisholm G, Huang X, Huang H, Ergun MA, Gangnon R, Sprague BL, Plevritis S, Feuer E, de Koning HJ, Cronin KA. Collaborative Modeling of the Benefits and Harms Associated With Different U.S. Breast Cancer Screening Strategies. Ann Intern Med 2016; 164:215-25. [PMID: 26756606 PMCID: PMC5079106 DOI: 10.7326/m15-1536] [Citation(s) in RCA: 194] [Impact Index Per Article: 24.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Controversy persists about optimal mammography screening strategies. OBJECTIVE To evaluate screening outcomes, taking into account advances in mammography and treatment of breast cancer. DESIGN Collaboration of 6 simulation models using national data on incidence, digital mammography performance, treatment effects, and other-cause mortality. SETTING United States. PATIENTS Average-risk U.S. female population and subgroups with varying risk, breast density, or comorbidity. INTERVENTION Eight strategies differing by age at which screening starts (40, 45, or 50 years) and screening interval (annual, biennial, and hybrid [annual for women in their 40s and biennial thereafter]). All strategies assumed 100% adherence and stopped at age 74 years. MEASUREMENTS Benefits (breast cancer-specific mortality reduction, breast cancer deaths averted, life-years, and quality-adjusted life-years); number of mammograms used; harms (false-positive results, benign biopsies, and overdiagnosis); and ratios of harms (or use) and benefits (efficiency) per 1000 screens. RESULTS Biennial strategies were consistently the most efficient for average-risk women. Biennial screening from age 50 to 74 years avoided a median of 7 breast cancer deaths versus no screening; annual screening from age 40 to 74 years avoided an additional 3 deaths, but yielded 1988 more false-positive results and 11 more overdiagnoses per 1000 women screened. Annual screening from age 50 to 74 years was inefficient (similar benefits, but more harms than other strategies). For groups with a 2- to 4-fold increased risk, annual screening from age 40 years had similar harms and benefits as screening average-risk women biennially from 50 to 74 years. For groups with moderate or severe comorbidity, screening could stop at age 66 to 68 years. LIMITATION Other imaging technologies, polygenic risk, and nonadherence were not considered. CONCLUSION Biennial screening for breast cancer is efficient for average-risk populations. Decisions about starting ages and intervals will depend on population characteristics and the decision makers' weight given to the harms and benefits of screening. PRIMARY FUNDING SOURCE National Institutes of Health.
Collapse
Affiliation(s)
- Jeanne S. Mandelblatt
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Natasha K. Stout
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Clyde B. Schechter
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Jeroen J. van den Broek
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Diana L. Miglioretti
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Martin Krapcho
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Amy Trentham-Dietz
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Diego Munoz
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Sandra J. Lee
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Donald A. Berry
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Nicolien T. van Ravesteyn
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Oguzhan Alagoz
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Karla Kerlikowske
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Anna N.A. Tosteson
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Aimee M. Near
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Amanda Hoeffken
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Yaojen Chang
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Eveline A. Heijnsdijk
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Gary Chisholm
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Xuelin Huang
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Hui Huang
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Mehmet Ali Ergun
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Ronald Gangnon
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Brian L. Sprague
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Sylvia Plevritis
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Eric Feuer
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Harry J. de Koning
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| | - Kathleen A. Cronin
- From Georgetown University Medical Center and Cancer Prevention and Control Program, Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC; Harvard Pilgrim Health Care Institute, Dana-Farber Cancer Institute, and Harvard Medical School, Boston, Massachusetts; Albert Einstein College of Medicine, Bronx, New York; Erasmus MC, University Medical Center Rotterdam, Rotterdam, the Netherlands
- UC Davis School of Medicine, Davis, Stanford University, Stanford, and University of California, San Francisco, San Francisco, California; Group Health Research Institute, Seattle, Washington; Information Management Services, Calverton, and National Cancer Institute, Bethesda, Maryland; Carbone Cancer Center, University of Wisconsin, Madison, Wisconsin; University of Texas MD Anderson Cancer Center, Houston, Texas
- Norris Cotton Cancer Center and Dartmouth Institute for Health Policy and Clinical Practice, Geisel School of Medicine at Dartmouth, Hanover, New Hampshire; and College of Medicine, and University of Vermont, Burlington, Vermont
| |
Collapse
|
38
|
Miranda-Diaz C, Betancourt E, Ruiz-Candelaria Y, Hunter-Mellado RF. Barriers for Compliance to Breast, Colorectal, and Cervical Screening Cancer Tests among Hispanic Patients. INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH 2015; 13:ijerph13010021. [PMID: 26703676 PMCID: PMC4730412 DOI: 10.3390/ijerph13010021] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 08/14/2015] [Revised: 10/13/2015] [Accepted: 10/15/2015] [Indexed: 11/16/2022]
Abstract
Hispanics are less likely to undergo screening tests for colorectal cancer and cervical cancer than non-Hispanic whites. Compliance with mammography, fecal occult blood testing (FOBT), colonoscopy, and cervical smears (PAP) and barriers for compliance were studied. A descriptive study was performed with 194 ambulatory patients while they attended routine medical visits. Women are more likely than men to undergo a colonoscopy. Conversely, FOBT was most likely reported by men. Reasons for compliance with FOBT differed by gender. Men were most likely to avoid FOBT due to lack of knowledge whereas women reported that physicians do not recommend the procedure. Both men and women reported that lack of physician's recommendation was their primary reason for not undergoing a colonoscopy. Men tend to report lack of knowledge about colonoscopy procedure. A higher mammogram utilization rate was reported by women older than 40 years. PAP smears were reported by 74% of women older than 21 years. The major reasons for avoiding mammography and PAP tests were having a busy schedule, fear, and feeling uncomfortable during the procedure. In a multivariate regression analysis, occupational status was found to be a predictor for compliance with FOBT and colonoscopy.
Collapse
Affiliation(s)
- Christine Miranda-Diaz
- Universidad Central del Caribe, School of Medicine, Cancer Research Unit, Internal Medicine Department, P.O. BOX 60327, Bayamon 00960-6032, Puerto Rico.
| | - Elba Betancourt
- Universidad Central del Caribe, School of Medicine, Cancer Research Unit, Internal Medicine Department, P.O. BOX 60327, Bayamon 00960-6032, Puerto Rico.
| | - Yelitza Ruiz-Candelaria
- Universidad Central del Caribe, School of Medicine, Cancer Research Unit, Internal Medicine Department, P.O. BOX 60327, Bayamon 00960-6032, Puerto Rico.
| | - Robert F Hunter-Mellado
- Universidad Central del Caribe, School of Medicine, Cancer Research Unit, Internal Medicine Department, P.O. BOX 60327, Bayamon 00960-6032, Puerto Rico.
| |
Collapse
|
39
|
Villa A, Gohel A. Oral potentially malignant disorders in a large dental population. J Appl Oral Sci 2015; 22:473-6. [PMID: 25591015 PMCID: PMC4307758 DOI: 10.1590/1678-775720140254] [Citation(s) in RCA: 25] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/08/2014] [Accepted: 09/11/2014] [Indexed: 11/24/2022] Open
Abstract
Objectives Oral cancer (OC) may be preceded by clinically evident oral potentially malignant disorders (OPMDs). Oral carcinogenesis is a multistep process that begins as epithelial hyperplasia and progresses to oral epithelial dysplasia and finally to fully malignant phenotypes. The aim of our study was to estimate the prevalence of OPMDs in a large population of dental patients. Methods Patients were seen in the Oral Diagnosis and Oral Medicine clinics at Boston University Henry M. Goldman School of Dental Medicine between July 2013 and February 2014 and received a comprehensive oral examination to identify any possible mucosal lesions. Patients with a suspected OPMD (submucous fibrosis, oral lichen planus, leukoplakia and erythroplakia) that did not resolve in 2–3 weeks received a biopsy for definitive diagnosis. Logistic regression models were used to explore the relationship between OPMDs and associated risk factors. Results A total of 3,142 patients received a comprehensive oral examination [median age: 43 (range: 18–97); 54.3% females]. Among these, 4.5% had an oral mucosal lesion with 0.9% being an OPMD (one submucous fibrosis, three epithelial dysplasias, fourteen with hyperkeratosis/epithelial hyperplasia and nine with oral lichen planus). Males and current smokers were associated with higher odds of having OPMD (OR 1.7, 95% CI 0.8–3.8; OR 1.9, 95%CI 0.8–4.1). Increasing age was associated with having OPMDs (p<0.01). Conclusion Optimal oral visual screening for OC remains a simple and essential tool to identify any suspicious lesions and potentially increase survival. Although OPMDs were rare, our results confirm the importance of a thorough chairside screening by dentists and dental students to detect any mucosal changes.
Collapse
Affiliation(s)
- Alessandro Villa
- Division of Oral Medicine and Dentistry, Brigham and Women's Hospital, Department of Oral Medicine, Infection and Immunity, Harvard School of Dental Medicine, Boston, MA, United States
| | - Anita Gohel
- Department of General Dentistry, Boston University Henry M. Goldman School of Dental Medicine, Boston, MA, United States
| |
Collapse
|
40
|
Molloi S, Ducote JL, Ding H, Feig SA. Postmortem validation of breast density using dual-energy mammography. Med Phys 2015; 41:081917. [PMID: 25086548 DOI: 10.1118/1.4890295] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/27/2022] Open
Abstract
PURPOSE Mammographic density has been shown to be an indicator of breast cancer risk and also reduces the sensitivity of screening mammography. Currently, there is no accepted standard for measuring breast density. Dual energy mammography has been proposed as a technique for accurate measurement of breast density. The purpose of this study is to validate its accuracy in postmortem breasts and compare it with other existing techniques. METHODS Forty postmortem breasts were imaged using a dual energy mammography system. Glandular and adipose equivalent phantoms of uniform thickness were used to calibrate a dual energy basis decomposition algorithm. Dual energy decomposition was applied after scatter correction to calculate breast density. Breast density was also estimated using radiologist reader assessment, standard histogram thresholding and a fuzzy C-mean algorithm. Chemical analysis was used as the reference standard to assess the accuracy of different techniques to measure breast composition. RESULTS Breast density measurements using radiologist reader assessment, standard histogram thresholding, fuzzy C-mean algorithm, and dual energy were in good agreement with the measured fibroglandular volume fraction using chemical analysis. The standard error estimates using radiologist reader assessment, standard histogram thresholding, fuzzy C-mean, and dual energy were 9.9%, 8.6%, 7.2%, and 4.7%, respectively. CONCLUSIONS The results indicate that dual energy mammography can be used to accurately measure breast density. The variability in breast density estimation using dual energy mammography was lower than reader assessment rankings, standard histogram thresholding, and fuzzy C-mean algorithm. Improved quantification of breast density is expected to further enhance its utility as a risk factor for breast cancer.
Collapse
Affiliation(s)
- Sabee Molloi
- Department of Radiological Sciences, University of California, Irvine, California 92697
| | - Justin L Ducote
- Department of Radiological Sciences, University of California, Irvine, California 92697
| | - Huanjun Ding
- Department of Radiological Sciences, University of California, Irvine, California 92697
| | - Stephen A Feig
- Department of Radiological Sciences, University of California, Irvine, California 92697
| |
Collapse
|
41
|
Associations between contextual factors and colorectal cancer screening in a racially and ethnically diverse population in Texas. Cancer Epidemiol 2015; 39:798-804. [PMID: 26651438 DOI: 10.1016/j.canep.2015.09.012] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/11/2015] [Revised: 09/25/2015] [Accepted: 09/26/2015] [Indexed: 12/30/2022]
Abstract
BACKGROUND Colorectal cancer is the third most commonly diagnosed cancer and the third leading cause of cancer death in the United States. Increased attention has been given to understanding the role of local contexts on cancer screening behaviors. We examined the associations between multiple tract-level socioeconomic measures and adherence to colorectal cancer screening (CRCS) in Harris County and the City of Houston, Texas. METHODS We conducted a cross-sectional multilevel study linking individual-level data on CRCS from the 2010 Health of Houston Survey with contextual data from the U.S. Census and the U.S. Department of Housing and Urban Development. We examined tract-level poverty, education, employment, income inequality, and foreclosure measures across 543 Census tracts. Analyses were limited to individuals aged 50-74 years (N=1720). RESULTS Overall, 58.0% of the sample was adherent to any recommended CRCS test. In bivariate analyses, increasing levels of area poverty, low education, unemployment, and foreclosures were associated with lower odds of adherence to CRCS. After controlling for individual-level covariates, only tract-level unemployment remained associated with adherence to CRCS (adjusted OR=0.80; 95% CI: 0.66-0.99; P=.037). CONCLUSIONS Neighborhood socioeconomic disadvantage is increasingly recognized as a determinant of health, and our study suggests that the contextual effect of area unemployment may extend to cancer screening outcomes. Our finding is important to cancer control planners because we identified a contextual marker of disparity that can be used to target local interventions to promote CRCS and thereby reduce cancer disparities among non-adherent individuals who reside in communities with high unemployment rates.
Collapse
|
42
|
Abstract
Colorectal cancer (CRC) is a complex disease that develops as a consequence of both genetic and environmental risk factors. A small proportion (3-5%) of cases arise from hereditary syndromes predisposing to early onset CRC as a result of mutations in over a dozen well defined genes. In contrast, CRC is predominantly a late onset 'sporadic' disease, developing in individuals with no obvious hereditary syndrome. In recent years, genome wide association studies have discovered that over 40 genetic regions are associated with weak effects on sporadic CRC, and it has been estimated that increasingly large genome wide scans will identify many additional novel genetic regions. Subsequent experimental validations have identified the causally related variant(s) in a limited number of these genetic regions. Further biological insight could be obtained through ethnically diverse study populations, larger genetic sequencing studies and development of higher throughput functional experiments. Along with inherited variation, integration of the tumour genome may shed light on the carcinogenic processes in CRC. In addition to summarising the genetic architecture of CRC, this review discusses genetic factors that modify environmental predictors of CRC, as well as examples of how genetic insight has improved clinical surveillance, prevention and treatment strategies. In summary, substantial progress has been made in uncovering the genetic architecture of CRC, and continued research efforts are expected to identify additional genetic risk factors that further our biological understanding of this disease. Subsequently these new insights will lead to improved treatment and prevention of colorectal cancer.
Collapse
Affiliation(s)
- Ulrike Peters
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
- Department of Epidemiology, University of Washington School of Public Health, Seattle, WA, USA
| | - Stephanie Bien
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| | - Niha Zubair
- Public Health Sciences Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA
| |
Collapse
|
43
|
Young L, Kim J, Wang H, Chen LW. Examining Factors Influencing Colorectal Cancer Screening of Rural Nebraskans Using Data from Clinics Participating in an Accountable Care Organization: A Study Protocol. F1000Res 2015; 4:298. [PMID: 26339476 PMCID: PMC4544372 DOI: 10.12688/f1000research.6782.1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Accepted: 07/20/2015] [Indexed: 01/05/2023] Open
Abstract
Background: Although mortality rates of colorectal cancer (CRC) can be significantly reduced through increased screening, rural communities are still experiencing lower rates of screening compared to urban counterparts. Understanding and eliminating barriers to cancer screening will decrease cancer burden and lead to substantial gains in quality and quantity of life for rural populations. However, existing studies have shown inconsistent findings and fail to address how contextual and provider-level factors impact CRC screening in addition to individual-level factors. Purpose: The purpose of the study is to examine multi-level factors related to CRC screening, and providers’ perception of barriers and facilitators of CRC screening in rural patients cared for by accountable care organization (ACO) clinics. Methods/Design: This is a convergent mixed method design. For the quantitative component, multiple data sources, such as electronic health records (EHRs), Area Resource File (ARF), and provider survey data, will be used to examine patient-, provider-, clinic-, and county-level factors. About 21,729 rural patients aged between 50 and 75 years who visited the participating ACO clinics in the past 12 months are included in the quantitative analysis. The qualitative methods include semi-structured in-depth interviews with healthcare professionals in selected rural clinics. Both quantitative and qualitative data will be merged for result interpretation. Quantitative data identifies “what” factors influence CRC screening, while qualitative data explores “how” these factors interact with CRC screening. The study setting is 10 ACO clinics located in nine rural Nebraska counties. Discussion: This will be the first study examining multi-level factors related to CRC screening in the new healthcare delivery system (i.e., ACO clinics) in rural communities. The study findings will enhance our understanding of how the ACO model, particularly in rural areas, interacts with provider- and patient-level factors influencing the CRC screening rate of rural patients.
Collapse
Affiliation(s)
- Lufei Young
- College of Nursing, Lincoln Division, University of Nebraska Medical Center, Omaha, NE, 68198, USA
| | - Jungyoon Kim
- Department of Health Service Research and Administration, University of Nebraska Medical Center, College of Public Health, Omaha, NE, 68198, USA
| | - Hongmei Wang
- Department of Health Service Research and Administration, University of Nebraska Medical Center, College of Public Health, Omaha, NE, 68198, USA
| | - Li-Wu Chen
- Department of Health Service Research and Administration, University of Nebraska Medical Center, College of Public Health, Omaha, NE, 68198, USA
| |
Collapse
|
44
|
Kemp Jacobsen K, O'Meara ES, Key D, S M Buist D, Kerlikowske K, Vejborg I, Sprague BL, Lynge E, von Euler-Chelpin M. Comparing sensitivity and specificity of screening mammography in the United States and Denmark. Int J Cancer 2015; 137:2198-207. [PMID: 25944711 DOI: 10.1002/ijc.29593] [Citation(s) in RCA: 42] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2015] [Revised: 04/20/2015] [Accepted: 04/23/2015] [Indexed: 11/06/2022]
Abstract
Delivery of screening mammography differs substantially between the United States (US) and Denmark. We evaluated whether there are differences in screening sensitivity and specificity. We included screens from women screened at age 50-69 years during 1996-2008/2009 in the US Breast Cancer Surveillance Consortium (BCSC) (n = 2,872,791), and from two population-based mammography screening programs in Denmark (Copenhagen, n = 148,156 and Funen, n = 275,553). Women were followed-up for 1 year. For initial screens, recall rate was significantly higher in BCSC (17.6%) than in Copenhagen (4.3%) and Funen (3.1%). Sensitivity was fairly similar in BCSC (91.8%) and Copenhagen (90.5%) and Funen (92.5%). At subsequent screens, recall rates were 8.8%, 1.8% and 1.4% in BCSC, Copenhagen and Funen, respectively. The BCSC sensitivity (82.3%) was lower compared with that in Copenhagen (88.9%) and Funen (86.9%), but when stratified by time since last screen, the sensitivity was similar. For both initial and subsequent screenings, the specificity of screening in BCSC (83.2% and 91.6%) was significantly lower than that in Copenhagen (96.6% and 98.8%) and Funen (97.9% and 99.2%). By taking time since last screen into account, it was found that American and Danish women had the same probability of having their asymptomatic cancers detected at screening. However, the majority of women free of asymptomatic cancers experienced more harms in terms of false-positive findings in the US than in Denmark.
Collapse
Affiliation(s)
- Katja Kemp Jacobsen
- Department of Public Health, University of Copenhagen, Copenhagen K, Denmark
| | | | - Dustin Key
- Group Health Research Institute, Seattle, WA, USA
| | | | - Karla Kerlikowske
- Department of Epidemiology and Biostatistics, University of California, San Francisco, CA, USA.,General Internal Medicine Section, Department of Veterans Affairs, University of California, San Francisco, CA, USA
| | - Ilse Vejborg
- Center of Diagnostic Imaging, Copenhagen University Hospital, Rigshospitalet, Denmark
| | - Brian L Sprague
- Department of Surgery, University of Vermont, Burlington, VT, USA
| | - Elsebeth Lynge
- Department of Public Health, University of Copenhagen, Copenhagen K, Denmark
| | | |
Collapse
|
45
|
van Ravesteyn NT, Stout NK, Schechter CB, Heijnsdijk EAM, Alagoz O, Trentham-Dietz A, Mandelblatt JS, de Koning HJ. Benefits and harms of mammography screening after age 74 years: model estimates of overdiagnosis. J Natl Cancer Inst 2015; 107:djv103. [PMID: 25948872 DOI: 10.1093/jnci/djv103] [Citation(s) in RCA: 50] [Impact Index Per Article: 5.6] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/18/2014] [Accepted: 03/17/2015] [Indexed: 12/25/2022] Open
Abstract
BACKGROUND The aim of this study was to quantify the benefits and harms of mammography screening after age 74 years, focusing on the amount of overdiagnosis of invasive breast cancer and ductal carcinoma in situ (DCIS). METHODS Three well-established microsimulation models were used to simulate a cohort of American women born in 1960. All women received biennial screening starting at age 50 years with cessation ages varying from 74 up to 96 years. We estimated the number of life-years gained (LYG), quality-adjusted life-years, breast cancer deaths averted, false-positives, and overdiagnosed women per 1000 screens. RESULTS The models predicted that there were 7.8 to 11.4 LYG per 1000 screens at age 74 years (range across models), decreasing to 4.8 to 7.8 LYG per 1000 screens at age 80 years, and 1.4 to 2.4 LYG per 1000 screens at age 90 years. When adjusted for quality-of-life decrements, the LYG decreased by 5% to 13% at age 74 years and 11% to 22% at age 80 years. At age 90 to 92 years, all LYG were counterbalanced by a loss in quality-of-life, mainly because of the increasing number of overdiagnosed breast cancers per 1000 screens: 1.2 to 5.0 at age 74 years, 1.8 to 6.0 at age 80 years, and 3.7 to 7.5 at age 90 years. The age at which harms began to outweigh benefits shifted to a younger age when larger or longer utility losses because of a breast cancer diagnosis were assumed. CONCLUSION The balance between screening benefits and harms becomes less favorable after age 74 years. At age 90 years, harms outweigh benefits, largely as a consequence of overdiagnosis. This age was the same across the three models, despite important model differences in assumptions on DCIS.
Collapse
Affiliation(s)
- Nicolien T van Ravesteyn
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM).
| | - Natasha K Stout
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Clyde B Schechter
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Eveline A M Heijnsdijk
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Oguzhan Alagoz
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Amy Trentham-Dietz
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Jeanne S Mandelblatt
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| | - Harry J de Koning
- Department of Public Health, Erasmus MC, Rotterdam, the Netherlands (NTvR, EAMH, HJdK); Department of Population Medicine, Harvard Medical School/Harvard Pilgrim Health Care Institute, Boston, MA (NKS); Departments of Family and Social Medicine and Epidemiology and Population Health, Albert Einstein College of Medicine, Bronx, NY (CBS); Department of Industrial and Systems Engineering (OA) and Carbone Cancer Center and Department of Population Health Sciences (ATD), University of Wisconsin-Madison, Madison, WI; Department of Oncology, Georgetown University Medical Center and Cancer Prevention and Control Program, Lombardi Comprehensive Cancer Center, Washington, DC (JSM)
| |
Collapse
|
46
|
Tsuchida J, Nagahashi M, Rashid OM, Takabe K, Wakai T. At what age should screening mammography be recommended for Asian women? Cancer Med 2015; 4:1136-44. [PMID: 25914223 PMCID: PMC4529351 DOI: 10.1002/cam4.468] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2015] [Revised: 03/15/2015] [Accepted: 03/29/2015] [Indexed: 01/15/2023] Open
Abstract
Although regular screening mammography has been suggested to be associated with improvements in the relative survival of breast cancer in recent years, the appropriate age to start screening mammography remains controversial. In November 2009, the United States Preventive Service Task Force published updated guidelines for breast cancer, which no longer support routine screening mammography for women aged 40–49 years, but instead, defer the choice of screening in that age group to the patient and physician. The age to begin screening differs between guidelines, including those from the Task Force, the American Cancer Society and the World Health Organization. It remains unclear how this discrepancy impacts patient survival, especially among certain subpopulations. Although the biological characteristics of breast cancer and peak age of incidence differ among different ethnic populations, there have been few reports that evaluate the starting age for screening mammography based on ethnicity. Here, we discuss the benefits and harm of screening mammography in the fifth decade, and re-evaluate the starting age for screening mammography taking ethnicity into account, focusing on the Asian population. Breast cancer incidence peaked in the fifth decade in Asian women, which has been thought to be due to a combination of biological and environmental factors. Previous reports suggest that Asian women in their 40s may receive more benefit and less harm from screening mammography than the age-matched non-Asian US population. Therefore, starting screening mammography at age 40 may be beneficial for women of Asian ethnicity in well-resourced countries, such as Japanese women who reside in Japan.
Collapse
Affiliation(s)
- Junko Tsuchida
- Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan
| | - Masayuki Nagahashi
- Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan.,Department of Medical Oncology, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan
| | - Omar M Rashid
- H. Lee Moffitt Cancer Center & Research Institute, 12902 Magnolia Drive, SRB 4.24012, Tampa, Florida, 33612
| | - Kazuaki Takabe
- Division of Surgical Oncology, Department of Surgery, Virginia Commonwealth University School of Medicine and the Massey Cancer Center, 1200 E. Broad Street, Richmond, Virginia, 23219
| | - Toshifumi Wakai
- Division of Digestive and General Surgery, Niigata University Graduate School of Medical and Dental Sciences, 1-757 Asahimachi-dori, Chuo-Ku, Niigata, 951-8510, Japan
| |
Collapse
|
47
|
Chai J, Shen X, Feng R, Cheng J, Chen Y, Zha Z, Jia S, Liang H, Zhao T, Sha R, Shi Y, Li K, Wang D. eCROPS-CA: a systematic approach toward effective and sustainable cancer prevention in rural China. BMC Cancer 2015; 15:233. [PMID: 25886568 PMCID: PMC4416351 DOI: 10.1186/s12885-015-1253-6] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/29/2014] [Accepted: 03/25/2015] [Indexed: 12/21/2022] Open
Abstract
Background Effective prevention against cancers depends heavily on sustained individual efforts practicing protective behaviors and avoiding risk factors in a complex sociocultural context, which requires continuous and personalized supports. Contemporary prevention relies primarily on strategies targeting general population with limited attention being paid to individualized approaches. This study tests a novel package called, in acronym of core intervention components, eCROPS-CA that leverages protective behaviors against over 80% leading cancers among high risk individuals via continuous and tailored counseling by village doctors. Methods/Design The study utilizes a quesi-RCT design involving 4320 high risk individuals selected, via rapid and detailed risk assessments, from about 72,000 farmers aged 35+ in 36 administrative villages randomized into equal intervention and delayed intervention arms. The intervention arm receives baseline and semiannual follow up evaluations plus eCROPS-CA for 5 years; while the control arm, only the baseline and follow-up evaluations for the first 5 years and eCROPS-CA starting from the 6th year if the intervention is proved effective. eCROPS-CA comprises electronic supports and supervision (e), counseling cancer prevention (C), recipe for objective behaviors (R), operational toolkit (O), performance-based incentives (P), and screening and assessment (S). Evaluation measures include: incidence and stage of the leading cancers, cancer-related knowledge, attitudes and practices; easy biophysical indicators (e.g., body mass index, blood pressure); intervention compliance, acceptance of the package. Discussion The prevention package incorporates key success factors in a synergetic way toward cost-effectiveness and long-term sustainability. It targets a set rather than any single cancer; choses village doctors as key solution to the widespread lack of professional manpower in implementing personalized and thus relatively sophisticated prevention; adopts real-time monitoring in reaching continuous improvement; utilizes smart web aids to enable prioritizing complex determinants of objective behaviors, linking counseling sessions happened at different time points and hence delivering highly coordinated prevention; uses 2-stage risk assessment models in identifying high risk individuals so as to focus on the most needed; applies standardized operation procedures in simplifying and smoothing behavior intervention yet ensuring delivery of essential steps and key elements. Trials registry ISRCTN33269053 Electronic supplementary material The online version of this article (doi:10.1186/s12885-015-1253-6) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Jing Chai
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Xingrong Shen
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Rui Feng
- Department of Literature Review and Analysis, Library of Anhui Medical University, Hefei, Anhui, China.
| | - Jing Cheng
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Yeji Chen
- Anhui Center for Disease Control and Prevention, Hefei, Anhui, China.
| | - Zhengqiu Zha
- Anhui Center for Disease Control and Prevention, Hefei, Anhui, China.
| | - Shangchun Jia
- Anhui Center for Disease Control and Prevention, Hefei, Anhui, China.
| | - Han Liang
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Ting Zhao
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Rui Sha
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China.
| | - Yong Shi
- Luan Center for Disease Control and Prevention, Luan, Anhui, China.
| | - Kaichun Li
- Luan Center for Disease Control and Prevention, Luan, Anhui, China.
| | - Debin Wang
- School of Health Service Management, Anhui Medical University, Hefei, Anhui, China. .,Collaboration Center for Cancer Control, First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
| |
Collapse
|
48
|
Zeng YJ, Zhang CD, Dai DQ. Impact of lymph node micrometastasis on gastric carcinoma prognosis: A meta-analysis. World J Gastroenterol 2015; 21:1628-1635. [PMID: 25663783 PMCID: PMC4316106 DOI: 10.3748/wjg.v21.i5.1628] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2014] [Revised: 07/24/2014] [Accepted: 11/11/2014] [Indexed: 02/06/2023] Open
Abstract
AIM: To investigate the prognostic significance of lymph node micrometastasis (LNMM) in patients with gastric carcinoma.
METHODS: Two reviewers independently searched electronic databases including PubMed, EMBASE, the Cochrane Database of Systematic Reviews, the Cochrane Controlled Studies Register, and the China National Knowledge Infrastructure electronic database between January 1996 and January 2014. Strict literature retrieval and data extraction were performed to extract relevant data. Data analysis was conducted using RevMan 5.2.4 software, and relative risks (RRs) for patient death in five years and recurrence were calculated. A fixed- or random-effects model was selected to pool and a forest plot was used to display RRs.
RESULTS: Twelve cohort studies containing a total of 1684 patients were identified. LNMM positivity was worse than LNMM negativity with regards to the number of patients who died in five years. The effects of LNMM positivity in patients with gastric cancer of different T-stages remain unclear. LNMM in patients with gastric carcinoma was also associated with a higher recurrence rate. With regards to the number of patients who died in five years, Asian patients were worse than European and Australian patients.
CONCLUSION: We recommend that LNMM should not be used as a gold standard for prognosis evaluation in patients with gastric cancer in clinical settings until more high quality trials are available.
Collapse
|
49
|
Documet P, Bear TM, Flatt JD, Macia L, Trauth J, Ricci EM. The association of social support and education with breast and cervical cancer screening. HEALTH EDUCATION & BEHAVIOR 2015; 42:55-64. [PMID: 25394824 PMCID: PMC4526257 DOI: 10.1177/1090198114557124] [Citation(s) in RCA: 51] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
BACKGROUND Disparities in breast and cervical cancer screening by socioeconomic status persist in the United States. It has been suggested that social support may facilitate screening, especially among women of low socioeconomic status. However, at present, it is unclear whether social support enables mammogram and Pap test compliance. PURPOSE This study examines the association between social support and compliance with mammogram and Pap test screening guidelines, and whether social support provides added value for women of low education. METHOD Data were from a countywide 2009-2010 population-based survey, which included records of 2,588 women 40 years and older (mammogram) and 2,123 women 21 to 65 years old (Pap test). Compliance was determined using the guidelines in effect at the time of data collection. RESULTS Social support was significantly related to mammogram (adjusted odds ratio = 1.43; 95% confidence interval [1.16, 1.77]) and Pap test (adjusted odds ratio = 1.71; 95% confidence interval [1.27, 2.29]) compliance after controlling for age, race, having a regular health care provider, and insurance status. The interaction between social support and education had a significant effect on Pap test compliance only among women younger than 40; the effect was not significant for mammogram compliance. CONCLUSION Social support is associated with breast and cervical cancer screening compliance. The association between education and cancer screening behavior may be moderated by social support; however, results hold only for Pap tests among younger women. Practitioners and researchers should focus on interventions that activate social support networks as they may help increase both breast and cervical cancer screening compliance among women with low educational attainment.
Collapse
Affiliation(s)
| | - Todd M Bear
- University of Pittsburgh, Pittsburgh, PA, USA
| | | | - Laura Macia
- University of Pittsburgh, Pittsburgh, PA, USA
| | | | | |
Collapse
|
50
|
Suh M, Choi KS, Lee YY, Park B, Jun JK. Cancer screening in Korea, 2012: results from the Korean National Cancer Screening Survey. Asian Pac J Cancer Prev 2015; 14:6459-63. [PMID: 24377550 DOI: 10.7314/apjcp.2013.14.11.6459] [Citation(s) in RCA: 44] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
We investigated the cancer screening rates for five types of cancer (stomach, liver, colorectal, breast, and cervix uteri) using data from the Korean National Cancer Screening Survey (KNCSS), which is a nationwide, annual cross-sectional survey. The eligible study population included cancer-free men 40 years of age and older and women 30 years of age and older. The lifetime screening rate and screening rate with recommendation were calculated. The lifetime screening rates for gastric, liver, colorectal, breast, and cervical cancers were 77.9%, 69.9%, 65.8%, 82.9%, and 77.1%, respectively. The screening rates with recommendation were 70.9%, 21.5%, 44.7%, 70.9%, and 67.9%, respectively. The most common reason for all types of cancer was "no symptoms, " followed by "lack of time" and "fear of the examination procedure. " Efforts to facilitate participation in liver and colorectal cancer screening among Korean men and women are needed.
Collapse
Affiliation(s)
- Mina Suh
- National Cancer Control Institute, National Cancer Center, Goyang, Republic of KoreaE-mail :
| | | | | | | | | |
Collapse
|